Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Biological Therapies

Grimstad Ø, Sawanobori Y, Vestergaard C et al. Exp Dermatol 2009;18:35–43.

Treatment of atopic dermatitis has not undergone the same revolution as treatment of psoriasis with the introduction of specifically targeted biological agents. In the present study, the authors report the results of treating NC/Nga mice, which are an animal model of atopic dermatitis, with monoclonal anti-interleukin-31 antibodies.

Interleukin-31 (IL-31) is a recently discovered cytokine that is predominantly produced by Th2 cells, although it can also be expressed by Th1 cells. Expression of IL-31 messenger RNA is upregulated in the skin of patients with atopic dermatitis, and transgenic mice that overexpress IL-31 have been found to develop chronic pruritus and subsequent excoriations from excessive scratching, similar to that observed in patients with atopic dermatitis.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles